Cooperative Agreement UG3DA047700

This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $640,000 to Olfa Thera, Inc. to develop new therapeutics targeting the OLFR78/OR51E2 receptor pathway in the carotid body. The goal is to identify OLFR78/OR51E2 agonists that can strongly stimulate carotid body activity and ventilation to reverse opioid-induced respiratory depression, without the side effects of existing...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,876 to conduct preclinical trials targeting the neuropeptide S (NPS) receptor to mitigate opioid taking and seeking behaviors in animal models. The goals of the project are to demonstrate proof-of-concept that NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation in rats, which could inform the...

Federal Cooperative Agreement Summary Mebias Discovery Inc. received a $9.42 million Cooperative Agreement from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded on July 1, 2025, with a completion date of June 30, 2027. The company is developing MEB-1170, a novel chemical entity designed as a maintenance medication for opioid use disorder (OUD) treatment. This research addresses significant limitations of existing FDA-approved OUD...

Federal Cooperative Agreement Award Summary Sparian Biosciences Inc. (doing business as Palion Therapeutics) received a $6.28 million cooperative agreement award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to support the clinical development of SBS-147, a first-in-class oral arylepoxamide agonist non-opioid pain treatment. The award, obligated on July 1, 2025, with a completion date of June 30, 2027, funds research and...

Cooperative Agreement Summary ATAI Therapeutics, Inc. received a $2.92 million Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective August 15, 2025 through June 30, 2027. The award funds the optimization and development of non-hallucinogenic 5-HT2A/2C receptor agonists as therapeutic candidates for opioid use disorder (OUD). ATAI will advance two lead chemical series (EGX-J and EGX-I) that leverage...

Federal Cooperative Agreement Summary George Washington University received a $2.1 million Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research evaluating oxytocin (OXT), an FDA-approved medication, as a novel therapeutic intervention for opioid-induced respiratory depression (OIRD). The research initiative, awarded July 1, 2025, with completion expected June 30, 2027, addresses the critical...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $405,625.00 to Florida International University to investigate the potential benefits of the autophagy activator TFEB in mitigating opioid use disorder (OUD) and overdose in mice. The research aims to evaluate how TFEB overexpression or knockdown impacts opioid-induced effects on mu-opioid receptor desensitization, internalization, and...

Federal Cooperative Agreement Summary The National Institute on Drug Abuse (NIDA) awarded The Washington University a $7.992 million Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) effective September 1, 2025, through August 31, 2027. The award supports the development of negative allosteric modulators (NAMs) at the mu opioid receptor (MOR) as a novel therapeutic approach to address the opioid crisis in the United States. The research team has identified...

The National Institute on Drug Abuse (NIDA) awarded The Washington University a 3-year, $2,337,729 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to study the impact of prenatal opioid exposure on placental and fetal brain development. The project, titled "The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta" (OPIOID BPP), aims to define the longitudinal effects of prenatal opioid exposure on...

Federal Cooperative Agreement Summary Cessation Therapeutics, Inc. received a $5.23 million Cooperative Agreement award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to advance the clinical development of CSX-1004, a human immunoglobulin G1 (IgG1) monoclonal antibody designed to provide prophylaxis against fentanyl and fentanyl analog overdose. The award, dated September 15, 2025, with a completion date of July 31, 2028,...